FeesSafety
Pluang+

Seed launches its DS-01 Daily Synbiotic at all Costco stores, expanding its market reach.

Market News
09 Nov 2026, 15:01 WIB
PRNewsWire
View Source
Bullish
Seed launches its DS-01 Daily Synbiotic at all Costco stores, expanding its market reach.

Seed, a microbiome science company, has launched its flagship product DS-01® Daily Synbiotic in a Costco-exclusive 100-count jar, marking its first entry into the club retail channel. This move significantly expands Seed's distribution, complementing its presence on Amazon, Target, and other retailers. The DS-01® product is clinically validated to improve digestive health and is backed by rigorous scientific research. Seed plans to continue expanding its product line and retail channels to reach a broader audience in the coming years.

Seed's launch of its flagship gut health supplement DS-01® at Costco provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: Out of 150 priced health-sector US stocks, 121 rose and 18 fell today. Notable movers include NUWE (Nuwellis Inc) at USD 4.72 with a +3.06% change and a typical hold time of 32 days, CTXR (Citius Pharmaceuticals Inc) at USD 0.54 with a -2.98% change and a 19-day hold, and LQDA (Liquidia Corporation Common Stock) at USD 45.67 with a +2.86% change and a 4-day hold time.

More News

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...

Market News
Neutral
1 hour ago
New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...

Company Fundamentals
Bullish
2 hours ago
Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...

Bearish
2 hours ago
Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...

Market News
Bullish
2 hours ago
ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App